Trial Outcomes & Findings for Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau (NCT NCT03907657)

NCT ID: NCT03907657

Last Updated: 2024-05-21

Results Overview

Each reader will evaluate kidney imaging using Contrast-Enhanced Ultrasound (CEUS) versus Brightness Mode Ultrasound (B-mode) in patients at risk for kidney lesions. A dichotomized Bosniak score was used for comparison. Dichotomized Bosniak score: 0= nonmalignant and 1=malignant or possibly malignant. Scores were averaged across all readers. Kidneys were assessed by CEUS and B-mode by three different readers.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

15 participants

Primary outcome timeframe

Baseline

Results posted on

2024-05-21

Participant Flow

Subjects were enrolled in one center in North Carolina, between 9/23/2019 - 02/13/2023. All considered subjects were eligible, consented, and completed the study. In total 29 kidneys were studied.

Participant milestones

Participant milestones
Measure
All Subjects
All Patients with genetic diseases at risk of kidney lesions.
Overall Study Subjects
STARTED
15
Overall Study Subjects
COMPLETED
15
Overall Study Subjects
NOT COMPLETED
0
CEUS
STARTED
15
CEUS
COMPLETED
15
CEUS
NOT COMPLETED
0
B Mode
STARTED
15
B Mode
COMPLETED
15
B Mode
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients With a Genetic Disease at Risk of Kidney Lesions
n=15 Participants
Patients with a genetic disease at risk of kidney lesions will be imaged using contrast-enhanced ultrasound with Perflutren.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
Race (NIH/OMB)
White
12 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
15 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline

Population: Patients with a genetic disease at risk of a kidney lesion were imaged using contrast-enhanced ultrasound with Perflutren and B-mode ultrasound. Twenty- nine kidneys belonging to fifteen patients were assessed.

Each reader will evaluate kidney imaging using Contrast-Enhanced Ultrasound (CEUS) versus Brightness Mode Ultrasound (B-mode) in patients at risk for kidney lesions. A dichotomized Bosniak score was used for comparison. Dichotomized Bosniak score: 0= nonmalignant and 1=malignant or possibly malignant. Scores were averaged across all readers. Kidneys were assessed by CEUS and B-mode by three different readers.

Outcome measures

Outcome measures
Measure
CEUS
n=29 Overall Number of Kidneys
Contrast-enhanced ultrasound (CEUS) technique was used to evaluate 29 kidneys belonging to 15 subjects.
B-Mode
n=29 Overall Number of Kidneys
Brightness Mode Ultrasound (B-mode) technique was used to evaluate 29 kidneys belonging to 15 subjects.
Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound
0.13 Dichotomized score
Interval 0.0 to 1.0
0.20 Dichotomized score
Interval 0.0 to 1.0

SECONDARY outcome

Timeframe: Baseline

Population: Patients with a genetic disease at risk of kidney lesions will be imaged using contrast-enhanced ultrasound with Perflutren.Twenty- nine kidneys belonging to fifteen patients were assessed.

Each reader will evaluate kidney imaging using Contrast-Enhanced Ultrasound (CEUS). Potentially malignant lesions were extracted from clinically performed magnetic resonance imaging (MRI) completed within 4 months of CEUS. Dichotomized Bosniak scores from CEUS were compared with MRI-derived malignancy scores. Dichotomized Bosniak scores: 0= nonmalignant and 1=malignant or possibly malignant. Scores were averaged across all readers.

Outcome measures

Outcome measures
Measure
CEUS
n=29 Overall Number of Kidneys
Contrast-enhanced ultrasound (CEUS) technique was used to evaluate 29 kidneys belonging to 15 subjects.
B-Mode
n=29 Overall Number of Kidneys
Brightness Mode Ultrasound (B-mode) technique was used to evaluate 29 kidneys belonging to 15 subjects.
Comparison in Radiologist's Lesion Evaluation: CEUS Versus Clinically Performed MRI
0.13 Dichotomized score
Interval 0.0 to 1.0
0.10 Dichotomized score
Interval 0.0 to 1.0

Adverse Events

Patients With a Genetic Disease at Risk of Kidney Lesions

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Melahat Canter

University of North Carolina Lineberger Comprehensive Cancer Center

Phone: 9199620000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place